Abstract: The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
January 9, 2024
Assignee:
ModernaTX, Inc.
Inventors:
Leif Karlsson Parinder, Regina Desirée Fritsche Danielson, Kenny Mikael Hansson, Li Ming Gan, Jonathan Clarke, Ann-Charlotte Eva Egnell, Kenneth Randall Chien
Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
November 28, 2023
Assignee:
Sung Kyun Biotech Co., Ltd.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The present invention relates to treatment and diagnosis of lung cancer and metastases thereof. More specifically, the invention relates to such therapeutic use of antigen sources providing immunogenic polypeptides comprising at least an immunogenic portion of a cancer cell associated protein, which preferably is a zona pellucida (ZP) protein, especially a ZP3 protein or the extracellular domain thereof, whereby the antigen source induces a cellular immune response against the lung cancer cells. The antigen source can be a proteinaceous composition comprising such immunogenic ZP polypeptide, a nucleic acid encoding the immunogenic ZP polypeptide, or a cell expressing or presenting the immunogenic ZP polypeptide. In addition, the invention relates to the therapeutic use of a T cell comprising a T cell receptor that binds an MHC-peptide complex, wherein the peptide is a peptide from the immunogenic ZP polypeptide.
Type:
Grant
Filed:
October 31, 2018
Date of Patent:
November 21, 2023
Assignee:
Pantarhei Bioscience B.V.
Inventors:
Herman Jan Tijmen Coelingh Bennink, Nafis Ahmed Rahman
Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.
Type:
Grant
Filed:
March 10, 2022
Date of Patent:
November 21, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Michael E. Dunn, Jia Su, Jason Mastaitis, Jesper Gromada, Lori C. Morton
Abstract: A method for preventing neutropenia or reducing the duration of neutropenia in a patient by administering therapeutically effective amount of a human hybrid (hy) Fc fused granulocyte colony stimulating factor (G-CSF) developed as next-generation G-CSF.
Abstract: The invention provides a method and kits for inhibiting integrin ?9?1 activity comprising contacting integrin ?9?1 or a binding partner of integrin ?9?1 with an isolated anti-integrin ?9 inhibitor, wherein the integrin ?9?1 activity is inhibited. In certain aspects, the present invention provides a novel intervention by targeting integrin ?9?1 with a functional blocking inhibitor (e.g., peptides or antibodies) to limit brain damage following reperfusion after ischemic stroke.
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Type:
Grant
Filed:
February 11, 2022
Date of Patent:
October 24, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
June 16, 2021
Date of Patent:
October 24, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Type:
Grant
Filed:
January 31, 2022
Date of Patent:
October 3, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
Abstract: Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma.
Abstract: Provided are a modified mesenchymal stem cell and culture supernatant thereof, and a pharmaceutical composition comprising said cell or culture supernatant thereof. The mesenchymal stem cell is capable of expressing: (1) a first protein, which is selected from FGF21 or a variant thereof, or a first fusion protein comprising the FGF21 or the variant thereof and (2) a second protein, which is selected from GLP-1 or a variant thereof or a second fusion protein comprising the GLP-1 or the variant thereof. Also provided is the use of the modified mesenchymal stem cell and culture supernatant thereof, and the pharmaceutical composition comprising said cell or culture supernatant thereof in the treatment of metabolic diseases and in the preparation of a medicament for treating metabolic diseases.
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
September 5, 2023
Assignee:
SUNG KYUN BIOTECH CO., LTD.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
August 22, 2023
Assignee:
Sung Kyun Biotech Co., Ltd.
Inventors:
Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
Abstract: The present invention relates to a method for prediction of response to cardiovascular regeneration comprising the use of biomarkers. Further, the present invention relates to a combination of the biomarkers for use in a method for prediction of response to cardiovascular regeneration, a computer device to perform a method according to the present invention and a device adapted for carrying out the inventive method.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
August 1, 2023
Assignee:
Universität Rostock
Inventors:
Gustav Steinhoff, Julia Nesteruk, Markus Wolfien
Abstract: The disclosure provides an ex vivo method to prepare regulatory T cells, a population of regulatory T cells with enhanced properties and methods of using the population or complexes useful to induce Tregs in a mammal. The ex vivo methods allows for the generation and expansion of super regulatory T cells for the prevention, inhibition or treatment of autoimmune disorders.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
July 18, 2023
Assignee:
University of Massachusetts
Inventors:
Gregory N. Tew, Lisa M. Minter, Emrah Ilker Ozay
Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
July 11, 2023
Assignees:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM RAINFOREST INNOVATIONS
Inventors:
Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
July 4, 2023
Assignee:
CELLECTIS SA
Inventors:
Cecile Schiffer-Mannioui, Philippe Duchateau, Anne-Sophie Gautron
Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
Type:
Grant
Filed:
May 29, 2019
Date of Patent:
July 4, 2023
Assignee:
Abcentra, LLC
Inventors:
Bertrand C. Liang, Stacey Ruiz, Christopher John Farina